semaglutide prediabetes weight loss trial progression to diabetes (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial or reach GLP-1 Receptor Agonists as Treatments

Over time, this can throw off the balance of nutrients the body needs, especially if meals are skipped in an attempt to accelerate results

They include: Nausea the most commonly reported symptom, typically peaking in the first one to two weeks after a dose change Diarrhoea and constipation both can occur, sometimes alternating Vomiting less common than nausea but reported by some patients at higher doses Abdominal discomfort or bloating Diet-related side effects occur when patients eat too little, too quickly, or consume high-fat meals

Gut health connection

Meal-stimulated plasma GLP-1 levels in response to a liquid meal test (187.5 ml, 450 kcal, 17.5 g fat, 54.0 g carbohydrate, 19.1 g protein, Abbott Ensure) were measured at baseline, fasted (0 min = T0) and 30 min after starting the liquid meal (T30)

You might have heard Semaglutide mentioned in conversations about weight loss breakthroughs

Date: February 25, 2016 Event: 2016 Noonday Concerts Location: Rubendall Recital Hall, Weiss Center for the Arts Chelsea Mia Pierre Works by: R